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Accumulating research indicates that individuals with asthma are at an increased risk for 
mild cognitive impairment; however, neural contributions to these detected neurocognitive 
deficits are yet to be elucidated. Recent neuroimaging studies in asthma observe volume 
reductions in the hippocampus, the primary neural region involved in memory, as well as 
alterations in the hippocampal chemical composition indicative of neuronal integrity. These 
studies highlight how both neural structure and chemical composition may be associated with 
detected neurocognitive deficits in asthma. However, to the best of our knowledge, no study has 
examined indicators of dynamic neural activity captured by blood oxygenated level dependent 
(BOLD) signal change through functional magnetic resonance imaging (fMRI) in patients with 
asthma during a neurocognitive task. Thus, the present study utilized fMRI to examine group 
differences in hippocampal signal change of neurocognitively intact individuals with and without 
asthma during a memory retrieval task, and their association with markers of peripheral 
physiology relevant to neurocognitive processes. 
While no group difference was observed in hippocampal signal change, whole-brain 
analyses revealed that individuals with asthma demonstrated greater signal change in the right 
inferior frontal cortex (IFC) when engaged in a memory retrieval task. Behaviorally, no group 
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differences were observed for total accuracy, but those with asthma were less accurate 
identifying previously observed faces. 
These findings corroborate previous studies suggesting that individuals with asthma 
perform poorer on some, but not all, behavioral tasks of neurocognition. Further, imaging 
analyses suggest that even younger adults with well controlled asthma may be working harder 
than those without asthma by recruiting additional areas of the right inferior frontal cortex (IFC) 
during memory retrieval. The present study continues to underscore the importance of studying 
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 Accumulating research supports the idea that individuals with asthma are at an increased 
risk for neurocognitive difficulties (Irani et al., 2017; Caldara-Alvarado et al., 2013). Despite 
decades of behavioral observations of these neurocognitive differences (Dunleavy et al., 1980; 
1981), there are only a handful of studies examining the brain in asthma (Davenport et al., 2000; 
VonLeupoldt et al., 2009; 2011; Rosenkranz et al., 2016; Ritz et al., 2019) and fewer with the 
intention of better understanding potential contributions to neurocognition (Brown et al., 2004; 
Carlson et al., 2017; Kroll et al., 2018; Bian et al., 2018). Here, the present understanding of 
neurocognition in asthma from behavioral, neural, and animal perspectives are discussed, with 
particular emphasis on the hippocampus - the primary neural region involved in memory and 
learning. Next, the potential roles of peripheral physiology (e.g. airway inflammation, endocrine 
response) and treatment related factors (e.g. asthma control, commonly utilized medications) in 
neurocognition and neural processes are discussed. These constructs will be considered in light 
of the present study which examined 1) hippocampal blood oxygen level dependent (BOLD) 
signal change, as an indirect indicator of neural activity, in patients with and without asthma 
during a memory task and 2) whether hippocampal signal during a memory task was associated 
with disease relevant peripheral physiology or treatment related factors.  
Asthma  
Asthma is a chronic inflammatory disease, characterized by hyperresponsiveness of the 
airways, which impacts up to 300 million people worldwide (GINA, 2020). Asthma is one of the 
few chronic diseases which occurs throughout the lifespan impacting both children and adults. 
The proportion of adults with asthma continues to increase globally (GINA, 2020). While 







asthma (GINA, 2020). Furthermore, in the US asthma disproportionally impacts those of lower 
socioeconomic status and racial minorities (CDC, 2019). Asthma is a largely heterogeneous 
disease, with patients experiencing varying degrees of chronic symptoms and intermittent acute 
exacerbations. Asthma disease processes consists of both airway inflammation and narrowing 
due to smooth muscle spasm and bronchoconstriction. These disease processes can additionally 
be exacerbated by environmental allergens or chemicals, postural changes including physical 
exertion, and even strong emotions (Ritz et al., 2010). Common physiological presentations of 
acute asthma exacerbation include symptoms of chest tightness, wheezing, cough, shortness of 
breath, and chest pain, and by definition vary over time and in intensity, together with variable 
expiratory airflow limitation (GINA, 2020), while chronic disease process can go unnoticed if 
not interfering with daily activities. As such, asthma control and consistent medication use is 
highly variable with national surveys estimating over 60% of adult patients have uncontrolled 
disease (CDC, 2019). Patients with asthma are treated not with a curative intent, but rather with 
the aim of achieving asthma control and preventing acute disease exacerbation. This is achieved, 
depending on disease severity, with a combination of various daily medications (e.g. 
corticosteroids, long acting bronchodilators) and self-administered quick-relief rescue 
medication. In the contexts of severe life-threatening exacerbations, asthma is often acutely 
managed with systemic steroids to achieve sufficient disease control. In addition to the 
staggering health, psychological, and economic burden of managing this chronic disease, 
accumulating research and meta-analytic studies suggest that individuals with asthma are at an 









Importance of Neurocognition in Asthma  
When cognitive performance is compromised in asthma, there are observed negative 
impacts on treatment adherence (O’Connor et al., 2005; Skloot et al., 2015) and disease control 
(Ray et al., 2015). Poorer neurocognitive performance is additionally associated in some samples 
with underreporting of severe asthma symptoms in children (Koinis-Mitchell et al., 2009), and 
even mortality (Belia et al., 2007). Furthermore, both fluid and crystalized cognitive abilities 
have independently observed associations with medication behavior in patients with asthma 
(O’Connor et al., 2015). While it is unclear the directional influence of this associations, poorer 
neurocognition leading to poorer disease control vs. poorer disease control contributing to 
neurocognitive difficulties, this body of research underscores the relevance of studying and 
incorporating measures of neurocognition in patient care to support both respiratory and brain 
health.   
Mild Cognitive Impairment in Asthma 
As early as the 1980’s, behavioral studies document discrepancies in neurocognitive 
performance in children with asthma compared to peers without asthma, particularly in children 
with severe presentation of the disease (Dunleavy et al., 1980; 1981). As neuropsychological 
testing in patients with asthma has progressed beyond measuring only one domain typical for the 
context of an academic environment (e.g. attention or executive function) to include testing 
across multiple neurocognitive domains (e.g. processing speed or various components of 
memory) in both children and adults, a growing body of research highlights an increased 
potential for mild neurocognitive deficits in patients with asthma across the lifespan.  
In both large domestic and international samples, elevated rates of neurocognitive 







patients with asthma (Chen et al., 2017; Caldara-Alvarado et al., 2013; Lavielle et al., 2015; Irani 
et al., 2017). Studies with the highest estimates observe a 78% increased rate of MCI in 
otherwise healthy individuals with asthma over the age of 55, while controlling for self-rated 
health status, depression, and anxiety (Caldara-Alvarado et al., 2013).  
In attempts to consolidate this literature across adults and children, Irani et al. (2017) 
categorized neurocognitive tasks into eight domains: global intellect, academic achievement, 
attention, processing speed, executive function, language, learning and memory, and 
visuospatial/visuoperceptual abilities. Through meta-analysis of 15 studies, they concluded that 
significant reductions in neurocognitive performance exist in asthma patients across all cognitive 
domains with small to medium effect sizes (pooled effect size of -0.33) (Irani et al., 2017). 
Strongest effects were identified in the broadest neurocognitive domains including: academic 
achievement (-0.61), executive functioning (-0.45), and attention (-0.45). Smaller, but still 
statistically significant effects, were identified in visuospatial functioning (-0.33), processing 
speed (-0.31), and learning and memory tasks (-0.20). The pooled effect was moderated by age 
(stronger deficits observed in younger patients, but no overall difference between child and adult 
studies), asthma severity (greater deficits with increased severity), gender (stronger deficits 
observed in males), minority background (stronger deficits observed in minority populations), 
and socioeconomic status (SES) (lower performance in those with annual household income < 
$15,000), emphasizing the relevance of the environmental and psychosocial context to 
neurocognitive performance in patients with asthma. While categorization between childhood 
and adult asthma samples did not statistically moderate their findings, the highest rates of MCI in 







As cross-sectional studies supporting neurocognitive impairment in asthma accumulate, a 
handful of studies in younger patients with less severe asthma do not find this association (Cohen 
et al., 2016) and several prospective medication manipulation studies suggest a likely 
impermanence of neurocognitive impairment. In one sample of young adults who at baseline had 
poorer neurocognitive performance on some but not all measures compared to healthy controls, 
poorer scores on domains where reductions were observed (e.g. focused attention, concentration, 
and processing capacity captured by the color-word chart of a Stroop Task and all components of 
the Paced Auditory Serial Addition Test), were associated with greater circadian variation in 
lung function (e.g. peak-flow variability, clinically utilized as an indicator of airway 
hyperresponsiveness or asthma control) (Weersnick et al., 1997). When peak-flow variability 
was successfully treated over a 6-week period (regardless of the type of asthma medication 
administered), neurocognitive performance subsequently improved to levels consistent with non-
asthmatic controls (Weersink et al., 1997). Some improvement was likely due to test-retest 
effects, as neurocognitive improvement was observed for both asthma patients and controls; 
however, this early study highlights three key points: 1)  baseline group differences in 
neurocognition are observed between patients with asthma and controls;  2)  neurocognition in 
patients with asthma is associated with disease related variables including disease control; and 
most importantly 3) neurocognition in patients with asthma is malleable and potentially ripe for 
intervention by more aggressive disease treatment or other interventions. Indeed, meta-analytic 
synthesis identifies disease severity as a moderator of neurocognitive deficits in asthma (Irani et 
al., 2017).  
Corroborating these findings, Bozek and colleagues stratified 359 older adults (>65 







from good cognition, mild cognitive impairment (MCI), to dementia) and treated them with 
asthma medication for one year. The patients' documented improvement in asthma control 
coincided with significant improvements in neurocognitive performance on the Mini Mental 
Status Exam (MMSE) (Bozek et al., 2010). Patients with baseline scores indicative of dementia 
demonstrated the greatest raw improvement (mean MMSE pre=18.2, post=21.9), although all 
patients saw improvements on the 30 point neurocognitive screener: MCI (mean MMSE 
pre=25.4, post=27.2), and good cognition (mean MMS pre=28.1, post=29.7) (Bozek et al., 
2010).  
Despite decades of accumulating research identifying neurocognitive deficits in 
individuals with asthma, the mechanisms or neurophysiological underpinnings for the increased 
risk of MCI in patients with asthma are, at this point, only speculative. Hypothesis for putative 
contributing factors to neurocognitive deficits in patients with asthma, based on other models of 
chronic respiratory disease, preclinical work, and animal models, include: intermittent hypoxia 
(Alberi et al., 2013), iatrogenic consequence of pharmacological treatment of disease (Dunleavy 
et al., 1981; Brown et al.,2009; 2013), cumulative consequences of chronic inflammatory disease 
processes (Lavielle et al., 2015), vulnerability to oxidative stress (Dozor, 2010), and/or comorbid 
conditions with known impact on neurocognition (e.g. sleep difficulty, psychiatric diagnoses, 
metabolic syndrome). Many of the proposed factors have established influences on neural 
circuits and central nervous system processes relevant to neurocognitive performance – 
particularly those of the hippocampus, the primary neural region for memory. Thus, the 
hippocampus is one of the first structures considered in efforts to examine neural correlates of 








Neural Correlates of Neurocognition in Asthma 
A nascent literature has examined neural contributions to neurocognitive performance in 
asthma, largely studying the hippocampus, the primary neural region involved in memory with 
an equally significant role in signal integration (Fan et al., 2017). “Declarative” or “explicit” 
memory are all terms used to describe hippocampal dependent memory referring to an ability to 
remember specific events and facts through direct efforts to access memories through conscious 
recollection. “Episodic” memory further specifies the ability to recall specific personal 
experiences which occur in a unique spatial and temporal context compared to “semantic 
memory”, which refers to accumulated knowledge about the world not depending on any specific 
event (Eichbaum 2017). Observations of neurocognitive deficits in asthma are quite broad 
spanning multiple domains; however, in the same Dallas Heart Study sample, used by Caldara-
Alvarado and colleagues to document the greatest observed increased risk (78%) for MCI in 
participants with asthma (Caldara-Alvarado et al., 2013), one of the most commonly missed 
items on the Montreal Cognitive Assessment (MoCA) by all participants, not just those with 
asthma, was delayed free recall, an episodic memory task, missed by 56% of individuals tested 
(Rossetti et al., 2011). Following hippocampal damage, episodic memory is frequently impaired 
even when semantic memory can remain relatively intact (Eichbaum, 2017), highlighting 
importance of understanding episodic memory and the hippocampus in patients with asthma.   
Hippocampus in Animal Models of Asthma. In murine models of asthma, chronic 
airway inflammation and labored breathing is demonstrated to impact the hippocampus, 
specifically with increased markers of neuroinflammation (Cd11b protein), neuronal loss, and 
damaged synaptic structure (Xia et al 2014; Guo 2013; Caulfield et al., 2017). In conjunction 







studies observe behavioral deficits (e.g. longer time spent on a plus maze task) used as a model 
for cognitive performance (Guo et al., 2013).  Allergen induced inflammatory challenges are 
additionally demonstrated to influence the CNS, observing post-allergen challenge increases 
neuronal nitric oxide synthase (nNOS) in the hippocampus (Chen et al., 2008; Basso et al., 
2003). Animal models highlight the influence of allergic sensitization and/or asthma disease 
processes on the hippocampus, yet the extent it may generalize to human physiology provides 
important targets for further exploration in human models.  
Neuroimaging of Hippocampus in Asthma. Only a handful of studies have examined 
the hippocampus in patients with asthma, to generate initial understanding. In a large study of 
middle-aged adults (n=1,287), the 10.8% who had an asthma diagnosis had, on average, smaller 
hippocampal volumes compared to aged matched controls without asthma (Carlson et al., 2017). 
Interestingly, these findings were driven by males. In addition, chemical metabolites indicative 
of neuronal integrity (as observed through markers of metabolic activity including N-acetyl 
aspartate and creatine) have been observed to be lower in the left hippocampus of a sample of 
young adults with asthma compared to age and gender matched healthy controls (Kroll et al., 
2018); however, gray matter volume differences were not observed in this region (Ritz et al., 
2019). This could potentially indicate a developmental trajectory of neural deterioration observed 
in the metabolically active hippocampi, which precedes the gross structural and behavioral 
deficits observed in middle to older aged asthma samples (Carlson et al., 2016; Caldara-Alvarado 
et al., 2013). Broad reductions in white matter integrity in a sample of middle-aged adults have 
additionally been associated with measures of executive function in one asthma sample; 
however, no findings were specific to the hippocampal areas (Bian et al., 2018).  
 







 Neural memory processes; however, do not occur in isolation. Indeed, Bian and 
colleagues observed that the broad white matter abnormalities in asthma patients, were 
associated with longer duration of asthma and poorer asthma control (Bian et al., 2018). As 
disease control and severity are significant moderators of neurocognition (Irani et al., 2017), 
further investigation into peripheral physiology of the asthma disease process which may 
contribute to neurocognition and neural memory circuits is warranted.  
Peripheral inflammation. Asthma is at its core a disease characterized by inflammation 
and airway hyperreactivity; however, it is multifactorial in nature with no single biomarker 
indicating its presence. Th2 cells have been identified as the primary culprits of allergic airway 
inflammatory responses in asthma, yet there is evidence for a predominantly Th1 subtype 
(Holgate et al., 2015). Oxidative stress may influence both Th1 and Th2 immune responses and 
activate additional pro-inflammatory cytokines through NF-kB prolonging the inflammatory 
state (Dozor, 2010). Despite the known inflammatory disease processes of asthma, it was not 
previously understood that biological processes in the periphery could influence the central 
nervous system, primarily due to the role of the blood-brain barrier (BBB). However, recent 
research has identified several mechanisms, by which systemic inflammation crosses the BBB, 
and can subsequently influence neural chemistry (Di Benedetto et al., 2017). Beyond the Th2 
driven eosinophilic model of asthma, several authors propose a Th1 driven systemic 
inflammatory influence on the CNS (Lavielle et al., 2015; Alberi et al., 2013).  Emerging 
evidence of “inflammaging” highlights the relationship between low-grade chronic peripheral 
Th1 mediated inflammation and the development of age-related diseases (Di Benedetto et al., 
2017), which may be an important contribution to neurocognitive impairment observed in 







CNS chemical profile through stimulation of the afferent vagal nerve or directly cross the BBB 
through non-disruptive (e.g., peripheral cytokines binding to endothelial cell receptors 
modulating BBB function) or disruptive changes (e.g. morphological change in tight-junctions 
and endothelial cell damage influenced by nitric oxide)  (Varatharaj & Galea, 2017). As pro-
inflammatory cytokine receptors are observed in high concentration on the hippocampus and 
prefrontal cortex (Rosano, Marsland, & Gianaros, 2011), examining peripheral inflammatory 
processes may be of particular importance to memory processes in asthma.  
In human neuroimaging studies, fractional exhaled nitric oxide (FeNO), clinically used as 
a marker of airway inflammation, is associated with neural glucose metabolism and BOLD 
response during tasks of emotion (Rosenkranz et al., 2016; 2017; Ritz et al., 2019); however, the 
extent to FeNO may be  associated with neural activity during memory retrieval in patients with 
asthma, to the best of our knowledge, has not been studied. While elevated fractional exhaled 
nitric oxide captures only one component of a complex inflammatory response in asthma, it may 
be an initial noninvasive methodology to capture a more non-specific airway inflammatory 
response on neurocognition and the hippocampus.   
Hypothalamic Pituitary Adrenal (HPA) Axis. An equally significant peripheral 
system, with innervations to the central nervous system, relevant to asthma is the hypothalamic 
pituitary adrenal (HPA) axis. The HPA-axis serves an essential role in learning and memory, by 
both consolidating learning and readying the body during the day for alertness and concentration 
(Schwab et al., 2012). The HPA-axis is regulated by negative feedback, largely from 
glucocorticoid end products, making it a natural point of intersection with many of the 
corticosteroid medications used to treat patients with asthma. As individuals with asthma, have 







Miysaka et al., 2018), this may be due to a biological process or as a direct consequence of 
medication treatment. A robust literature on HPA-axis in psychological processes identifies 
endocrine influence on neural regions important to memory, in particular the hippocampus 
(Wingfield & Wolf, 2014),  and cognitive performance (McEwen & Sapolsky, 1995; McEwen, 
2000). Sustained elevation of circulating glucocorticoids may lead to CNS consequences and can 
impede memory retrieval and overall cognitive performance, while acute elevation of cortisol 
can strengthen working memory (McEwen et al., 2012). In children with asthma, cortisol change 
in response to an ACTH stimulation test has been associated with stronger working memory 
performance on tasks of attention (additionally conceptualized as arousal) (Annett et al., 2005). 
Further interactions of the anti-inflammatory hormone cortisol and peripheral inflammation are 
observed in asthma (Ritz et al., 2011; 2015; Kroll et al., 2019), suggesting the potential for 
asthmatics with a blunted HPA-axis response to have exaggerated or prolonged immune 
responses. The extent to which the cortisol awakening response (CAR), which is purported to 
support the body in readying itself for any threats that may come during the day (Stadler et al., 
2016) may contribute to neurocognition or neural processes in asthma has yet to be established.  
 
Disease Relevant Factors. Multiple components of asthma pathology and treatment with 
observed neural sequelae are hypothesized as potential mechanisms contributing to cognitive 
performance deficits in asthma. The strongest moderators include disease control and disease 
severity (Irani et al., 2017), which encompass a range of behavioral, psychological, biological, 
and treatment related mechanistic hypotheses for the impact of asthma on the central nervous 
system (Caulfield et al., 2017). It is also plausible that disease processes may exert cumulative 
effects on the brain over time. While many of these facets of asthma are proposed as mechanisms 







duration), none have been formally examined in relation to neural activity during memory 
retrieval.  
 
Treatment Related Factors. The influence of asthma medication on the central nervous 
system is understudied and availability of systematic medication data is limited, yet emerging 
evidence supports the notion that asthma medication can indeed cross the BBB to either the 
detriment or benefit of CNS. Two types of commonly prescribed medications, oral and inhaled 
corticosteroids, and their potential impact on the CNS regarding relevant to neurocognition is 
discussed.  
 Oral corticosteroids are effective in accelerating disease control and could be expected 
to mitigate the influence of atopic asthma disease processes on the CNS; however, they exert a 
far-reaching systemic influence beyond the airways, which ultimately negatively influence the 
CNS and can lead to alterations in both cognitive performance, particularly with long-term use 
(Judd et al., 2014; Brown et al., 2007, 2009). Longer use and dosages at supraphysiological 
levels are associated with reduced hippocampal volume, reduced hippocampal N-acetyl aspartate 
(NAA) metabolite ratios, poorer declarative memory, and increases in both depressive and manic 
symptoms (Brown et al., 2002; 2004; 2008; Bender et al., 2002). Long-term oral corticosteroid 
treatment has additionally been observed to contribute to stunted growth and HPA-axis 
suppression in children (Aljebab et al., 2017), and more recent findings have shown that even 
short-term oral corticosteroid administration can lead to hippocampal volume reductions over 
days (Brown et al., 2015). 
Inhaled corticosteroids. Compared to oral corticosteroids, inhaled corticosteroids (ICS) 
have a more targeted influence on the airways and are recommended for long-term asthma 







ICS use was associated with higher levels of hippocampal metabolites indicative of neuronal 
integrity and cellular energy (Kroll et al., 2018), which coincides with animal models 
demonstrating inhaled budesonide as a protective treatment against chronic asthma-induced 
neuroinflammation (Xia et al., 2015). On the other hand, ICS in high doses can contribute to 
HPA axis suppression (for review see Dahl, 2006), although adrenal suppression has also been 
observed prior to ICS treatment in children, and improvements in HPA axis function has 
coincided with asthma remission after ICS treatment (Priftis et al., 2008). ICS may reach 
systemic circulation by deposition in the pulmonary airways or in the mouth, where it is 
swallowed. National guidelines therefore recommend rinsing mouth after ICS use to minimize 
potential systemic influence (NHLBI/NAEPP, 2007). It has also been proposed that long-term 
corticosteroid medication may influence dyspnea perception (von Leupoldt et al., 2007) through 
neural plasticity in the PAG or insular cortex (von Leupoldt et al., 2011). Thus, beyond their 
influence on the airways, ICS appear to have a broader impact on the CNS. Alternatively, ICS 
could exert their influence through the enhancement of asthma control, making their proper use 
protective against the potentially stronger negative consequences of poor asthma control. 
Neuroimaging studies will be essential to further examine these possibilities.  
 
Summary and Aims of the Present Study  
In efforts to continue to explore neural contributions to cognitive performance in asthma 
patients, the present study addresses the following aims: 1) compare memory retrieval accuracy 
between individuals with and without asthma; 2) compare BOLD % signal change in bilateral 
hippocampi during memory retrieval task between individuals with and without asthma; and 3) 
examine if signal change in hippocampus is associated with airway inflammation, HPA-axis 







performance including: asthma control, asthma severity, and disease duration. As no fMRI 
imaging studies have been done with memory retrieval previously in patients with asthma, we 
will additionally explore Aims 2 and 3 utilizing a data driven whole brain analysis approach.  
 As previous studies observe poorer performance on both global neurocognitive tasks and 
in specific domains of learning and memory in patients with asthma (Irani et al., 2017), we 
hypothesize that individuals with asthma will have less accurate performance than control 
participants on all components of the memory task. During the memory task, we further 
hypothesize that the BOLD signal in the hippocampus will be reduced in participants with 
asthma compared to those without asthma. As high concentration of proinflammatory cytokine 
receptors are observed in the hippocampus (Rosano et al., 2011), we predict that BOLD signal 
change in the hippocampus will be negatively associated with markers of airway inflammation 
(FeNO). As cortisol awakening response plays a role in memory consolidation and general 
alertness during the day and the hippocampus has been demonstrated to be sensitive to cortisol 
(McEwen, 2015), we predict that BOLD signal change in the hippocampus will be positively 
associated with cortisol awakening response. Finally, as poorer disease control and longer 
disease duration (Ritz et al., 2019a, Ritz et al., 2019b) have been associated with CNS alterations 
in asthma across a variety of regions (VonLeupoldt et al., 2011), we hypothesis that larger 
BOLD signal change in the hippocampus will be associated with poorer asthma control, greater 




 Participants were recruited and screened for eligibility over the phone then scheduled for 







questionnaires and physiological measurements capturing asthma control. Between the two 
sessions, participants complete three time points of saliva sampling at home and returned their 
samples to the lab. On the second session, participants went through a behavioral memory 
encoding task then a MR Imaging protocol, where blood oxygen level-dependent (BOLD) fMRI 
was used to capture signal change during a memory retrieval task.  
Participants 
Data for this study were obtained as part of a larger multimethod project on asthma and 
emotion conducted between February 2014 and March 2017.  Forty participants were screened 
for health and psychological contraindications and enrolled in the study: twenty with a 
physician’s diagnosis of asthma and twenty age- and gender matched control participants with no 
history of asthma or other respiratory disease.   
Participants were identified using both passive recruitment on two academic campuses 
and neighboring establishments (e.g. posting flyers in coffee shops, restaurants with community 
boards) and active recruitment by calling participants with asthma who participated in previous 
studies and consented to be re-contacted in the future to participate in research.   
All participants completed a phone screen and were eligible if they met the following 
criteria: over age 18, confirmed diagnosis of asthma from participant’s physician, access to a 
rescue inhaler, and spoke English as their first language. Participants were ineligible if they 
endorsed the following:  current clinically significant levels of depression; current or recent 
history (within 1 year) of substance related disorders including alcohol abuse (>20 drinks per 
week and/or 5 or more drinks on one occasion), recreational drug use, or tobacco use;  any 
lifetime experience of a manic episode or psychosis; claustrophobia; cardiovascular disease; 







asthma; or the use of corticosteroids (oral or injected) in the previous 3 months. All participants 
were additionally screened for the presence of orthopedic circumstances, metallic inserts (braces 
or orthodonture), or other conditions (e.g. pregnancy, recent tattoo) contraindicated for MR 
imaging. 
Participants with severe and uncontrolled asthma according to the National Heart, Lung, 
and Blood Institute’s Guidelines for the Diagnosis and Management of Asthma (NHLBI) were 
additionally excluded due to potential safety concerns inside of the scanner; however, no asthma 
exacerbations were experienced by any participant in the scanning environment (NHLBI, 2007). 
On the day of each study visit, spirometry was conducted according to NHLBI guidelines in 
order to assure that the participant’s forced expiratory volume (FEV1) was greater than seventy 
percent of their predicted value to ensure participant safety. No recruited participants were 
excluded due to spirometry or asthma severity.  
Participants with asthma brought their rescue medication with them to both sessions in 
case of emergency; however, no participant required use of rescue medications. Participants were 
additionally asked to refrain from using their rescue medication on the day of a study session and 
could reschedule their session if they needed to use their medication that day. No participants 
rescheduled their sessions due to medication use.  
 
Assessment Procedure 
  The Institutional Review Boards of both the University of Texas Southwestern Medical 
Center (UTSW) and Southern Methodist University (SMU) reviewed and approved the 
procedures used in the study. Written informed consent was obtained by all participants. Each 







compensated $100 for taking part in both sessions and students could alternatively elect to 
receive course credit. 
Behavioral Session. At the first session conducted at SMU, participants completed self-
report questionnaires, provided physiological measures of airway inflammation and lung 
function, and underwent brief neurocognitive screening. Participants were additionally instructed 
on how to complete take home saliva samples.  
At home. On the evening before and the morning of the second session participants 
completed three at-home salivary cortisol measures: right before they went to bed; immediately 
upon awakening; and 30 minutes after awakening. Participants returned saliva samples to lab on 
the day of the imaging session. 
MR Imaging Session.  At the second session conducted at UTSW Advanced Imaging 
Research Center, participants completed self-report questionnaires, physiological markers of 
airway inflammation and lung function, and a behavioral emotion identification task to encode 
facial stimuli (see Figure 1). Participants then underwent a neuroimaging MR protocol including: 
structural scan, passive viewing of emotional videos, the memory retrieval task of interest for the 
present study, and a spectroscopy scan. The order of scans was consistent for all participants. For 
additional details on the structural scans see Ritz et al., 2019b, passive viewing of emotional 
videos Ritz et al., 2019a and spectroscopy scans see Kroll et al., 2018.  
Measures  
Sample Characterization. Participants completed a demographic survey that assesses 
age, sex, race, ethnicity, height, weight, and handedness. As an index of socioeconomic status, 







Asthma History. An ad-hoc measure of current symptoms, history, medication use, 
allergies, and family history was completed by each participant with asthma.  
Neurocognitive Screener. Neurocognitive function was assessed with the brief cognitive 
screening tool, Montreal Cognitive Assessment (MoCA) designed to detect mild cognitive 
impairment (MCI) (Nasreddine et al, 2005). This 10-minute screening tool has demonstrated 
adequate test re-test reliability and internal consistency, yielding a Cronbach alpha of .83 with 
both individual tasks and composite scores reliably discriminating between patients with mild 
cognitive impairment and normal controls while controlling for effects of age and education 
(Nasreddine et al, 2005). Individuals are scored on a 30-point scale, with those scoring above 26 
“extremely unlikely to meet clinical and neuropsychological criteria for MCI even after 
extensive evaluation” (Nasreddine et al, 2005). Subsequent large studies determined mean 
MoCA total scores in a population without cognitive decline at 23.36, indicating that individuals 
scoring above 23 may lack any cognitive impairment (Rossetti et al, 2011). The MoCA 
demonstrates very good to good specificity for identifying normal controls (87%) and excellent 
sensitivity in identifying MCI (90%) with sensitivity calculated as the percentage of normal 
controls who scored at or above the cut off score of 26 (Nasreddine et al, 2005). In comparison to 
the Mini Mental Status Examination (MMSE), the MoCA has demonstrated superior sensitivity 
to detecting MCI (Nasreddine et al, 2005) and was selected for the present study due to the 
brevity of administration and used to characterize the sample and ensure no presence of moderate 
to severe neurocognitive deficits. The MoCA was scored by two trained raters (graduate student 
and undergraduate research assistant) to ensure accuracy.  
Forced Expiratory Volume in one second (FEV1).  Along internationally accepted 







(AM2, Jaeger/Toennies, Höchberg, Germany) was used to obtain the forced expiratory volume in 
one second (FEV1), and the percentage of predicted FEV1 (FEV1 %) based off of height, weight, 
and sex was scored (Quanjer et al., 1993). Participant scoring less than 70 FEV1 % predicted, 
indicative of severe or uncontrolled asthma (NHLBI, 2007), was a part of the exclusion criteria 
at each session; however, no participants scored less than 70% of their predicted value at any 
time during their participation.  FEV1 % predicted is used to characterize the sample and is 
additionally incorporated into the Asthma Control Questionnaire (ACQ).   
Questionnaires Participants (with and without asthma) completed a battery of 
questionnaires at the two in-person study sessions.  
Asthma Control Questionnaire (ACQ). Asthma control over the previous week was 
measured by the ACQ. This brief 7-item instrument has demonstrated high reliability 
(ICC=0.90) and adequate validity with other measures of general health status (SF-36) and 
asthma quality of life questionnaire (AQLQ) (Juniper et al, 1999). The ACQ consists of 7 
multiple choice items reflecting participants’ experience of asthma symptoms (e.g., “How much 
of the time did you wheeze?”,  “How much shortness of breath did you experience because of 
your asthma?”), symptom interference (e.g., “How often were you woken by your asthma during 
the night?”, ”How bad were your asthma symptoms when you woke up in the morning?”, “How 
limited were you in your activities?”) and medication use (“How many puffs of a short-acting 
bronchodilator have you used each day?”). Participants ranked items from a 0 – 6 scale, with 0 
indicating the absence of symptoms and 6 indicating most severe ranking of symptoms 
Asthma Control Test (ACT). Asthma control over the past four weeks was measured by 
the ACT at the first session. This 5 item self-report instrument has demonstrated good internal 







ACT consists of 5 multiple choice questions, reflecting the participants’ experience of asthma 
symptoms (e.g. “How often have you had shortness of breath?”), daytime interference (“How 
much of the time did your asthma keep you from getting as much done at work, school, or at 
home?”), nighttime interference (“How often did your asthma symptoms wake you up at night or 
earlier than usual in the morning?”), medication use (“How often have you had to use your 
rescue inhaler or nebulizer medication?”), and perception of asthma control (“How would you 
rate your asthma control during the past 4 weeks?”). All items are equally weighted with total 
scores ranging from 5 (poor control) to 25 (total control) (Nathan et al, 2004). Both the ACT and 
ACQ have been designated as core instruments for National Institutes of Health initiated clinical 
research trials in adults (Jia et al, 2013). 
 
Physiological Assessments.   
 
Fractional Exhaled Nitric Oxide (FeNO). The fraction of nitric oxide in exhaled breath 
in ppb, FeNO, is clinically used as an indicator of airway inflammation. Nitric oxide is produced 
throughout the body and serves in various anti-inflammatory roles. As such, a variety of immune 
cells activated in allergic asthma produce large amounts of nitric oxide making it useful as a 
biomarker of peripheral airway inflammation (Barnes, Dweik, & Gelb, 2010; Dweik et al., 
2011). As diet and physical exertion are known to impact FeNO, all participants were instructed 
to refrain from eating an hour before their session and rinsed their mouth with water before 
capturing FeNO. FeNO was measured as participants kept a steady exhale of 10 seconds into a 
handheld electrochemical analyzer (Niox Mino; Aerocrine, Solna, Sweden).  
Cortisol Awakening Response (CAR). Participants provided samples of saliva by cotton 
swab (Salivette, Sarstedt, Germany) at three time points on the day before and say of their second 







time of saliva sampling directly on the Salivette and stored their samples in their home freezer 
until samples to the imaging session with an ice pack to prevent any sample denaturing due to an 
additional freeze-thaw cycle. Salivettes were frozen until the completion of data collection. 
While longer storage times of earlier collected may potentially present additional variability, 
salivary cortisol is stable for years at both -80 ºC and -60 ºC (Stadler et al., 2016). Saliva samples 
were analyzed at The University of Texas Southwestern Medical Center's, Biosciences Core in 
one batch to minimize any variability due to extraction procedures. Salivettes were spun at 
1600xg for 3 minutes to obtain saliva for analyses. Standards and quality controls (QCs) were 
spiked with phosphate-buffered saline (PBS). 100 microliters of samples, standards, and QCs 
were precipitated with 200ul of crash containing: methanol, formic acid (0.15% final 0.1%) and 
D4 Cortisol (Sigma-Aldrich, final 10ng). The tubes were incubated at room temperature for 10 
minutes and centrifuged at 13,200 rpm for 5 minutes at 4 ̊C in a standard micro-centrifuge. 
Aliquots of ~250 microliters supernatant were transferred to HPLC vials and analyzed by liquid 
chromatography-mass spectrometry (LC-MS/MS). Values from the three analytical runs were 
averaged, with an average CV% calculated. Any samples with values ≤.025 were identified as 
below the detection limit and recorded as .025 ng/ml. CAR was calculated from two time points 
as the absolute difference between awakening and thirty minutes after awakening (Stadler et al., 
2016). For additional procedures see Kroll et al., 2019. 
MR Imaging Session. The MR imaging session consisted of four separate components: 
1) questionnaire data as described above, 2) physiological measures of FeNO and spirometry as 
described above, 3) memory encoding behavioral task, and 4) MR scanning protocol.  
Memory Encoding Behavioral Task.  Prior to entry into the scanning environment, 







Participants viewed each face with five choices of emotion (i.e. happy, sad, anger, fear, or 
neutral) presented below the face. In order to ensure participants were attending and encoding 
facial stimuli, participants verbalized their response for the experimenter, who recorded it 
manually. Stimuli were colored faces from previous neuroimaging studies of emotion 
identification originally selected from a larger database (Gur et al. 2002) and have previously 
been used utilized in neuroimaging studies of emotion (Wolf et al., 2011; Satterwhaite et al., 
2011).  Images in this task are not associated with elicitation of arousal (Britton, et al., 2006), 
and they were not intended to elicit any change in the participant’s affective state.  Faces were 
displayed for 5.5 seconds, separated by a jittered inter-stimulus interval (ISI) between 500 
milliseconds to 18.5 seconds where a complex crosshair was displayed (see Figure 1). Each 
emotion was displayed 12 times, with no face displayed more than once. Total number of items 
accurately identified was calculated for each participant and used for analyses. 
 
Figure 1.  
 








Memory encoding task was presented to all participants by computer to encode facial stimuli 
prior to entering the scanning environment. To ensure appropriate attention, participants verbally 
responded with their selection of the emotion that best described each face out of the following 
emotions: happy, sad, anger, fear, or neutral. A total of 60 images (50% male, 12 of each 
emotion) were presented in a standardized order for 5.5 seconds, separated by a variable interval 
between 500 milliseconds to 18.5 seconds where a complex crosshair (center) was displayed.  
 
MR Image Acquisition. Participants were placed in a light helmet with a mirror to both 
allow participant to view stimuli presented on screen placed behind the participant and to reduce 
artifact associated with head movement. BOLD fMRI was acquired with a 3 Tesla (3T) Philips 
Achieva scanner equipped with a 32-channel head coil at UTSW Advanced Imaging Research 
Center. Functional images were acquired using an Echo Planar Imaging (EPI) sequence with the 
following parameters: repetition time (TR)=1500 ms, echo time (TE)=30 ms, voxel size = 3.4 x 
3.4 x 4.0 mm, flip angle=70°, field of view (FOV)=220 x 220 x 116 mm, matrix size=64 x 64, 39 
axial slices and 292 volumes per run; in some instances, field of view placement excluded the 
most dorsal regions of the brain. Five dummy volumes were discarded at the beginning of the 
scan to allow for T1 stabilization. For anatomical reference and to aid spatial normalization to 
standard atlas space, a high resolution anatomical image was acquired for each participant using 
magnetization-prepared rapid gradient-echo (MPRAGE) sequence: TR/TE/TI=8.2/3.8/873 ms, 
voxel size=1.0 × 1.0 × 1.0 mm, flip angle=12°; FOV=256 × 256 mm, 160 sagittal slices.  
fMRI Memory Retrieval Task. As the last task of the MR protocol, participants 
completed a facial memory retrieval task (Figure 2). In the retrieval task, participants were 
presented with faces from the encoding task or new emotional faces taken from the same 
database (Gur et al., 2002). Participants made a binary decision if the image was “New,” in that 
they had not seen the face before or, “Old,” in that they had seen the face in the previous task. 







Presentation software (Neurobehavioral Systems, Albany, CA) and responded using their right 
hand on the button box. A total of 60 faces in an event-related design was presented with an 
inter-stimulus interval between 500 milliseconds to 18.5 seconds. Each emotion was displayed 
12 times, with no face displayed more than once.  Participants were not informed ahead of time 
that they would be asked to remember the faces presented during the memory encoding task, 
completed approximately 60 minutes prior to entry in the scanner.  
 
Figure 2.  
 
fMRI Memory Retrieval Task  
 
Memory retrieval task was presented to all participants while they were in the scanner. 
Participants responded using a button box placed in their dominant hand to indicate if a face was 
either old (presented in the encoding task) or new (had not seen the face previously). A total of 
60 images (50% new, 50% male, 12 of each emotion) were presented in a standardized order for 
2.5 seconds, separated by a variable interval between 500 milliseconds to 18.5 seconds where a 












Data Analysis  
Statistical analyses were conducted using SPSS 26.0 (IBM Corp., 2019) and FSL 
(Woolrich et al., 2004). An alpha level of 0.05 was used as the significance criterion for 
hypothesis tests. Behavioral and peripheral data were screened for normality (skew cutoff=1, 
kurtosis cutoff=3), univariate outliers, and impossible values. As previously demonstrated, FeNO 
tends to have a skewed distribution (Ritz et al., 2019b) and was therefore log transformed and 
used in analyses. Independent sample t-tests and χ2 tests were used to compare groups on 
demographics and sample characteristics (e.g. lung function, BMI, neurocognitive screener). As 
previously published from a larger number of subjects from this sample (Ritz et al., 2019; Kroll 
et al., 2019), we hypothesized that participants with asthma will have greater levels of FeNO and 
a lower cortisol awakening response (CAR) compared to those without asthma (Ritz et al., 2019; 
Kroll et al., 2019). 
Behavioral analyses 
Independent sample t-tests were used to compare group differences in memory task 
accuracy. Spearman rank order correlations were used to examine task accuracy with 
physiological assessments for all participants (e.g. lnFeNO), and with disease control, severity 
and duration in participants with asthma. As inhaled corticosteroid (ICS) use likely influences 
the HPA axis by negative feedback, thereby dampening endogenous cortisol levels (Stadler et al., 
2016), all correlations examining association with CAR utilized Pearson partial correlations, to 
control for presence of a current inhaled corticosteroid prescription (yes/no). As individuals with 
asthma have previously observed reductions in neurocognitive domains of attention, learning & 
memory, and processing speed (Irani et al., 2017), we hypothesized that participants with asthma 







episodic memory (Ennis et al., 2016) and peripheral inflammation may contribute to 
neurocognitive deficits (Bradburn et al., 2018), we further hypothesized that poorer task 
accuracy would be correlated with lower CAR and higher lnFeNO. In individuals with asthma, 
we hypothesized that poorer task accuracy will be associated with poorer disease control, longer 
disease duration, and greater disease severity. 
MR Image Analysis 
fMRI data were preprocessed and analyzed using FEAT (FMRI Expert Analysis Tool) 
Version 6.00, part of FSL (FMRIB's Software Library, www.fMRIb.ox.ac.uk/fsl). Registration to 
high resolution structural and/or standard space images was carried out using FLIRT, with 
images coregistered to participant space and normalized into T1 Montreal Neurologic Institute 
(MNI) space using trilinear interpolation (Jenkinson 2002). The following pre-statistics 
processing was applied: motion correction using MCFLIRT with 12-df affine transformation 
using the median image in each time series as the template and by including FSL’s motion 
outliers as a regressor of no interest to account for any variance due to motion, TR double 
gamma (Jenkinson 2002); slice-timing correction using Fourier-space time-series phase-shifting; 
non-brain removal using BET with robust brain center estimation (Smith 2002); spatial 
smoothing using a Gaussian kernel of FWHM 8.0mm; grand-mean intensity normalization of the 
entire 4D dataset by a single multiplicative factor; high pass temporal filtering (Gaussian-
weighted least-squares straight line fitting, with sigma=50.0s). Time-series statistical analysis 
was carried out using FILM with local autocorrelation correction (Woolrich et al., 2001). All 
events were modeled in the GLM after convolution with a double-gamma hemodynamic 
response function. The time series model included viewing of old and new faces. Due to the 







Judd et al., 2014), current inhaled corticosteroid (ICS) prescription (y/n) was coded 0, 1 then 
mean centered and used as a nuisance regressor and separately examined for potential of an 
independent positive and negative impact. Mixed-effects analyses using FLAME (FMRIB's local 
analyses of mixed effects) were performed to conduct one-sample t-tests on subject-level whole-
brain contrasts.    
An event-related first-level model was specified, in which events were modeled with a 
custom three column format and convolved with a double-gamma hemodynamic response 
function. Each component of the memory retrieval task (old, new, old-new, new-old, all faces) 
was modeled separately.  
To examine between-group differences of participants with and without asthma, all first-
level contrasts were entered into an independent sample t-test random-effects analysis. Regions 
of interest (ROI) for the left and right hippocampus were then defined as with the Harvard-
Oxford Subcortical Map Atlas in FSL, and binary unweighted anatomical masks were generated 
using FSLeyes. ROI analyses were then performed using FSL’s featquery. Significant clusters of 
activation within each ROI were identified based on a statistical threshold of z=2.0, p<.05, and 
the mean percent signal change across all voxels was extracted for each participant and entered 
into SPSS for correlational analyses with other behaviors and physiological measures of interest.  
Independent sample t-tests were used to compare activity in bilateral hippocampi during 
memory retrieval task between groups (asthma vs. control): 1) viewing of old stimuli; 2) viewing 
of new stimuli; 3) contrast of old > new stimuli and 4) contrast of new > old stimuli. We 
hypothesized that bilateral hippocampi would demonstrate greater activity during all components 








Spearman rank order correlations were used to examine associations among hippocampal 
% signal change during memory task with behavioral performance on task (e.g. accurate old, 
accurate new, total accuracy), peripheral physiology (FeNO), and for individuals with asthma, 
asthma control (ACT, ACQ), asthma duration, and asthma severity. As inhaled corticosteroid use 
likely influences the HPA axis by negative feedback dampening endogenous cortisol levels 
(Stadler et al., 2016), Pearson partial correlations, controlling for current ICS prescription 
(yes/no), were used to examine any association with CAR. We hypothesized that in individuals 
with asthma, greater hippocampal signal change will be associated behavioral task accuracy,  
lower CAR, higher FeNO, poorer asthma control, longer asthma duration, and greater asthma 
severity. We did not make any a priori hypothesis for left vs. right hippocampus or viewing old 
vs. new stimuli.  
Exploratory Whole-Brain Analyses 
 While the hippocampus is the primary neural region associated with memory, memory 
retrieval is an integrative process influenced by many neural areas and the modulation of 
memory retrieval is not yet fully understood (Roozendaal, et al, 2009).  As such, exploratory 
voxelwise analyses with the conservative family-wise error (FWE) correction of p(FWE)<0.0001 
were conducted for the specific contrasts and analyses outlined above to identify any group 
differences in neural activity outside of hippocampus. As clusters did not survive correction at 
the most stringent threshold (z=3.1 p<.0001), analyses were run at corrected level of z=2.0, 
p<.05). Clusters that passed the thresholding, were then used in an exploratory fashion to 
generate a functionally defined ROI for the contrast asthma>controls of a general task effect of 
seeing all faces. A binary unweighted ROI mask was generated using fslmaths, which was then 







SPSS. Spearman rank order correlation were utilized to examine associations between signal 
change during task with task accuracy, peripheral physiology (FeNO), asthma control (ACT, 
ACQ), asthma duration, and asthma severity.  Pearson partial correlations, controlling for ICS, 
were used for examining an association with CAR.  
Results 
Of the 40 participants enrolled, all participants completed the entire procedure. At the 
fMRI preprocessing stage, data were excluded due to motion and data abnormality. Of 
participants with usable MRI data, task performance data was unavailable for one participant 
with asthma due to error with button box. All results are reported for those with available 
imaging data.     
Sample Characterization 
 Final analyses were based on 32 participants, 15 with asthma and 17 controls, who were 
young to middle aged with no obvious neurocognitive deficits. Those with asthma had mostly 
well-controlled disease. No group differences were observed on demographic variables.  
(Table 1).  
Table 1 
 
Sample Characteristics and Group Comparisons 
 Asthma (n=15)             Control (n=17) 
 Mean SD Mean SD p 
Age, yrs. 25.13 9.25 25.06 9.56 0.98 
Sex      
  % Male 53.33  56.25  0.88 
BMI 23.81 3.96 25.40 5.09 0.34 
MoCA (0-30) a  27.88 2.19 27.40 2.64 0.59 
Education, yrs. 14.90 2.83 15.13 3.43 0.57 
Race (%)     0.52 
   White 53.33  52.94   







   Asian   6.66    0.00   
   Multiracial 20.00  11.76   
   Other 20.00    5.88   
Ethnicity (%)     0.74 
   Non-Hispanic/Latinx 80.00  76.47   
   Hispanic/Latinx 20.00  23.53   
FeNO (ppb) 60.84 57.66 20.0 13.90 0.003** 
FEV1 % Predicted 95.04 11.17 100.00 20.00 0.54 
Asthma Severity b (%)      
  Intermittent 20.00  N/A   
  Mild, Persistent 46.67  N/A   
  Moderate, Persistent 26.67  N/A   
  Severe, Persistent 6.67  N/A   
Asthma Control       
   ACT (5-25) 20.27 3.86    
   ACQ (0-6) 0.97 0.56    
Inhaled Corticosteroids (%) 26.66  N/A   
 Fractional Exhaled Nitric Oxide (FeNO), Forced Expiratory Volume in One Second (FEV1), 
Montreal Cognitive Assessment (MoCA); ACT, Asthma Control Test; ACQ, Asthma Control 
Questionnaire. Note, independent samples (two-tailed) t-test found no statistically significant 
difference between groups on demographic variables. Ranges of questionnaire scores are 
provided in parentheses after each measure. ACT is scored with higher values indicating better 
control and ACQ is scored with lower values indicating better control. aMoCA scores <23 
indicative of mild cognitive impairment, Rosetti et al., 2011, bNIH/NAEPP (2007) severity and 
medication step therapy guidelines, *p < .05, **p < .01 
 
Task Performance 
 Task accuracy for all participants was low (mean 55% accuracy), with no difference 
between old (mean 55%) or new faces (mean 55%). While there was no group difference in 
overall task accuracy, individuals with asthma identified old faces (mean 49.5%) less accurately 




Group Comparisons between Task Performance and Cortisol Awakening Response  







 Mean SD Mean SD t p 
Accurate, All (0-60)  33.14 4.44 33.41 5.04 -0.16 0.88 
Accurate, Old (0-30) 14.93 3.20 17.82 3.00 -2.59 0.02* 
Accurate, New (0-30) 18.21 4.92 15.24 5.09 1.64 0.11 
 Asthma (n=14) Control (n=16)   
CAR 1.02 1.32 2.96 2.39 -2.44 .021* 
Ranges of possible scores are provided in parentheses after each measure. Cortisol Awakening 
Response (CAR), *p < .05 
 
Group Differences in Peripheral Physiology 
 As expected, results of the independent sample t-test indicated that individuals with 
asthma had lower CAR compared to those without asthma, t(28)=-2.47, p=0.021 (Table 2). For 
individuals with asthma, FeNO was on average high (mean >60 ppb) and, as anticipated, 
significantly greater in individuals with asthma, t(28)=3.19, p=.003 (Table 1).    
Associations Among Task Performance and Peripheral Physiology 
 For all participants, Spearman nonparametric analyses revealed that total task accuracy 
was neither significantly correlated with lnFeNO rs(27)= -0.182, p= 0.36, nor with CAR rs(29)= 
0.033, p= 0.87. Spearman correlations examining associations among each type of stimuli (old 
faces accuracy, new faces) and lnFeNO and CAR did not reveal significant findings.  For 
individuals with asthma, task accuracy was not significantly correlated with lnFeNO, CAR, 
asthma disease severity, duration, or control (Table 3).  
Table 3  
 
Spearman Rank order Correlations among Task Performance, lnFeNO, CAR, and Asthma 
Duration, Control and Severity for Individuals with Asthma (n=15) 





Task Accuracy  
(All faces) 







Task Accuracy  
(Old faces) 
-0.099 0.171 -0.192 0.206 0.126 -0.200 
Task Accuracy  
(New faces) 
-0.100 -0.326 -0.050 -0.335 0.080 -0.412 
lnFeNO -- 0.332 0.315 -0.118 -0.283 0.329 
CARa  -- 0.327 -0.077 0.015 0.129 
Asthma Duration   -- 0.197 -0.163 0.068 
Asthma Severity    -- -0.364 0.439 
ACT     -- -0.800** 
ACQ       -- 
Natural Log of Fractional Exhaled Nitric Oxide (lnFeNO), Cortisol Awakening Response 
(CAR), Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Note: ACT is 
scored with higher values indicating better control and ACQ is scored with lower values 
indicating better control. aPearson partial correlations were used for CAR to control for ICS use, 
*p < .05, **p <.01 
 
Task Response  
 The examination of all trials (both old and new faces) revealed significant BOLD signal 
change, as an indirect marker of neural activation, for the task in distributed regions including 
bilateral frontal, occipital, and thalamic, consistent with studies examining face recognition 
(Satterwhaite et al., 2009). No clusters survived thresholding at z= 2.0, p<. 05 for old > new or 
new < old contrasts, indicating no statistically significant difference in signal change when 
participants viewed old compared to new faces during the memory task. 
Hippocampal Region of Interest Analyses 
 No differences in signal change were observed between individuals with or without 
asthma in either hippocampi when viewing old or new stimuli (Table 4).  
Table 4 
 







 Asthma (n=15)  Control (n=17) 
 Mean SD Mean SD t p 
LHC Average (Old) 0.083 0.155 0.068 0.121 0.32 0.76 
LHC Average (New) -0.198 0.104 -0.891 0.149 1.51 0.14 
RHC Average (Old) 0.076 0.171 0.844 0.123 -0.15 0.88 
RHC Average (New) -0.013 -0.115 -0.731 0.155 1.23 0.23 
Left Hippocampus (LHC), Right Hippocampus (RHC) 
 
 
 Behaviorally, Spearman correlations revealed that participants with asthma who 
demonstrated greater % signal change in the right hippocampus (RHC) when viewing new faces 
were less accurate on the total task accuracy for all faces, r(14)= -0.538, p= 0.047. These 
associations were neither observed bilaterally, nor when viewing  but significant associations 
were not revealed while viewing old faces or with the left hippocampus (LHC).  
Table 5 
Spearman Correlations among Hippocampal % Signal Change and Task Accuracy in patients 
with asthma (n=15) 






LHC Average (Old) -0.011 -0.100 0.165 
LHC Average (New) 0.049 0.062 0.002 
RHC Average (Old) 0.169 0.175 0.085 
RHC Average (New) -0.538* -0.182 -0.343 
Left Hippocampus % Signal Change (LHC), Right Hippocampus % Signal Change (RHC), *p < 
.05 
 
 For participants with asthma, there was a trend level only association in the hypothesized 







approached significant association with greater asthma severity, rs(14)= -0.454, p= 0.089 (Table 
6).  
 
Table 6  
 
Spearman Correlations among Hippocampal % Signal Change, Asthma Control, Disease 
Duration and Asthma Severity (n=15) 
 Asthma Control      






-0.188 0.009 -0.220 0.105 0.064 -0.454+ 
LHC Average 
(New) 
0.165 -0.097 0.016 0.595 0.177 0.147 
RHC Average 
(Old) 
0.248 -0.253 0.104 0.344 -0.035 -0.250 
RHC Average 
(New) 
-0.217 0.291 -0.319 0.269 0.454+ 0.204 
Left Hippocampus % Signal Change (LHC), Right Hippocampus % Signal Change (RHC), 
Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Note: ACT is scored with 
higher values indicating better control and ACQ is scored with lower values indicating better 
control. aPearson partial correlations were used for CAR to control for ICS use, *p < .05, +p < .10 
 
 
Exploratory Whole-Brain Analyses 
 In order to examine brain regions beyond those selected in the a priori analyses, we 
performed a whole-brain analyses of the asthma > control and control > asthma contrasts when 
viewing old faces, new faces, old > new, new > old faces, and all faces. While there was no 
difference between viewing old and new faces, the R. Inferior Frontal Cortex (IFC) showed 
significantly greater BOLD response in those with asthma compared to controls when viewing 











Unique response of R. Inferior Frontal Cortex during memory task for Asthma > Control contrast  
 
Presented in Neurological view. Note: Colored bar indicates z thresholds ranging from 2.00-7.00. 




Regions of significant whole-brain analysis % signal change for group level comparison 
(contrast: asthma > control) 
     MNI 
Region Cluster Size, mm3 Z Max p x y z 
R. Inferior Frontal Cortex       
    Old Faces 2259 4.89 0.046    32 58 28 
    New Faces 2949 3.49 0.014  48 32 0 
    All Faces 4242 4.11 0.001 34 58 28 
Old Faces > New Faces 0      
New Faces > Old Faces 0      
Z maps thresholded at family-wise error of p<0.05 (cluster corrected, z=2.0).  
R, right, MNI, Montreal Neurologic Institute.  
 
 
 In patients with asthma, Spearman nonparametric correlations did not reveal any 
associations among signal change in this cluster defined ROI or overall behavioral performance 
on total task accuracy rs(14)=-0.131, p=0.655, task accuracy for old faces  rs(14)=-0.153, p= -







correlations additionally did not reveal any associations among signal change and lnFeNO, 
rs(14)=-.071, p=0.817. Pearson partial correlations, controlling for ICS, did not reveal any 
association among signal change in cluster defined ROI and CAR r(11)=-0.254, p=0.401. 
Spearman correlations did reveal a significant association between signal change in cluster 
defined ROI and asthma duration, rs(14)=-0.521, p=0.047, suggesting that the longer a patient 
has suffered from asthma, the smaller the signal change in the right inferior frontal cortex when 
engaged in a memory task.  
 
Table 7  
 
Spearman Correlations among functionally defined ROI % Signal Change, Asthma Control, 
Disease Duration and Asthma Severity (n=15) 
 Asthma Control    
 ACT ACQ Disease Duration Asthma Severity  
R. Inferior Frontal Cortex     
     All Faces 0.127 -0.084 -0.521* -0.391 
Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ) Note: ACT is scored with 
higher values indicating better control and ACQ is scored with lower values indicating better 





 The primary goal of the present study was to compare individuals with asthma to those 
without asthma at both behavioral and neural levels during a memory retrieval task, in efforts to 
elucidate potential neural contributions to the increasingly identified neurocognitive deficits in 
patients with asthma. It was hypothesized that individuals with asthma would have less accurate 
behavioral performance on the memory task than controls, and that signal change in the 
hippocampus would be reduced in participants with asthma during the memory task. To test 







completed a facial memory task. Behavioral results largely confirmed previous findings, as 
individuals with asthma had poorer performance on some, but not all measures of memory 
retrieval task. On a neural level and contrary to our prediction, no group differences in 
hippocampal signal change were observed. In efforts to study the brain-behavior relationship in 
asthma, we additionally compared hippocampal signal change with task accuracy and measures 
of peripheral physiology and disease processes with previously observed or purported influences 
on neurocognition. Exploratory whole brain analyses revealed that during memory task, those 
with asthma had greater signal change in the right inferior frontal cortex (IFC) compared to those 
without asthma. The implications and limitations of these findings are discussed below.  
 First, a generalized inspection of the within subject imaging data revealed that all groups 
demonstrated significant and broad signal change in regions of the occipital, thalamic and 
bilateral frontal regions while completing the facial memory task. These findings are consistent 
with studies examining facial recognition and demonstrate that participants were appropriately 
engaged in the task. (Satterwhaite et al., 2009, Wolf et al., 2011). Behaviorally, the task was 
quite difficult with average accuracy of 55%, providing sufficient opportunity for variability of 
behavioral measures.  
 
Second, as is previously observed in dozens of studies (Irani et al., 2017), individuals 
with asthma performed poorer than healthy controls on some, but not all, behavioral measures of 
neurocognition. Specifically, individuals with asthma performed poorer on accurately identifying 
old faces, a task which captures one’s ability not only to retrieve but also successfully encode a 
memory. Interestingly, participants with asthma were similarly accurate at correctly identifying 
if a face was new or old as their age and gender matched control groups. This may indicate that 







which only emerge during challenging tasks, but they are similarly successful at a slightly 
different neurocognitive task of selectivity. Indeed, behavioral studies do observe significant 
reductions in learning and memory in patients with asthma but with smaller effect sizes 
compared to domains of executive function or attention (Irani et al., 2017). Contrary to 
expectation, performance on this task was not associated with any markers of peripheral 
physiology or asthma disease. As this was a single task and markers of peripheral physiology 
(e.g. FeNO and CAR) used in the present study are non-invasive and likely several biological 
pathways removed from direct influences on neurocognition or neural circuitry, the null results 
in this young sample with generally well-controlled asthma were not surprising. Overall, 
behavioral findings are consistent with previous literature in that patients with asthma 
inconsistently demonstrate poorer performance on tasks for neurocognition. It may be important 
for future studies to ensure sufficient challenge in learning and memory tasks, to capture more 
subtle group differences that may emerge prior to the onset of clinically relevant neurocognitive 
deficits.  
Third, the primary aim of this study was to compare signal change in bilateral 
hippocampi in individuals with and without asthma, where we anticipated that less signal change 
would be observed in patients with asthma compared to controls during the memory task. While 
the memory task demonstrated sufficient difficulty as outlined above, no group differences in 
hippocampal signal were observed during the task. These null findings may be most 
parsimoniously attributed to lack of neural activity differences during a memory task in this 
young and well controlled sample, not presenting with any obvious neurocognitive difficulties or 
complaints. Although group differences have been observed in the hippocampal metabolic 







observed in middle aged individuals with asthma (Carlson et al., 2016), it may be that any 
consequences of this disease has yet to impact a related but distinct process of hippocampal 
neural activity captured with the BOLD signal.  
Within the asthma group, ROI analyses of the right hippocampus (RHC) revealed that 
greater signal change while viewing new faces was associated with poorer accuracy on the 
memory task of all faces. Although statistically significant, this correlational finding provides 
only tentative support for a relation between greater RHC activity and accuracy and should be 
cautiously interpreted. One potential interpretation could be that the greater the effort spent 
attempting to discriminate from new faces results in less total accuracy.  
 Fourth, exploratory whole brain analyses revealed that individuals with asthma have 
greater signal response during the memory task generally, in a cluster likely representing the 
right inferior frontal cortex (IFC). The MNI standardized z-max coordinates entered in to 
Neurosynth.org, a meta-analytic tool to compare signal changes across studies, identified studies 
observing signal increases in the similar  peaks in response to viewing emotional faces 
(Loughead et al., 2008). Consistent with our results, there appears to be a greater prevalence of 
studies observing signal changes in the right vs. left IFC. Both of these concepts are consistent 
with the type of stimuli presented in the current study. While exploratory in nature, this finding 
for the first time suggests that individuals with asthma may be working harder than those without 
asthma by recruiting additional areas to engage with the same task. Correlational findings with 
asthma disease processes suggest that, less signal change in the functionally defined ROI of the 
right IFC during the memory task was associated with a longer disease duration. Again, these 
findings should be interpreted cautiously; however, it suggests potential for differential neural 







decrease in activation in some regions or may alternatively indicate influence of learning or 
efficiency of neural response.   
 Taken together, these findings are largely consistent with behavioral studies observing 
neurocognitive performance differences in individuals with asthma on some but not all tasks and  
suggest that individuals with asthma may be working harder at a neural level than those without 
asthma to achieve the same overall task accuracy.  
 
Limitations 
 The present study has several limitations. Most notably, the smaller sample size recruited 
and available for final analyses limits the generalizability of these findings and the study was 
likely underpowered to detect more subtle pre-clinical differences in neural signal. Furthermore, 
this was a relatively young and well-educated sample. A majority of those presenting with 
asthma had well controlled disease, which likely restricted the range of our variables and limited 
opportunities to detect group differences or associations. Further, many of the factors proposed 
to impact neurocognition and neural circuitry that coincide with poor disease control in asthma 
may not be relevant for this sample (e.g. comorbid medical conditions or chronic use of systemic 
steroids to achieve asthma control). 
Second, the specifics of study design may have limited our ability to detect a more subtle 
difference neural hippocampal signal if one does exist. Encoding rather than retrieval may yield 
greater hippocampal signal change (Zeineh et al., 2003), and the technical challenges of imaging 
the hippocampus with the present design, may obscure more detailed responses from 
hippocampal subregions. The functional voxel size of, 3.4 x 3.4 x 4.0 mm, likely averages 







1 x 1 x 1 mm. Additionally, given the nature of the task, there is most certainly an affective 
component contributing to the memory process.   
Despite these limitations of the study, our ability to observe any group differences with 
the whole brain analyses in individual this young of age without neurocognitive difficulties, 
suggests that even in fairly well-controlled patients with asthma, pre-clinical differences in 
neural activity during memory tasks might be present.   
 
Future Directions  
 Future studies are needed with variability in the known risk factors for poorer 
neurocognition in asthma: low socioeconomic status, poor asthma control, and racial minorities 
(Irani et al., 2017). As age is a risk factor for poorer neurocognition generally, extending this 
study with a lifespan approach to examine an asthma by aging interaction hypothesis is 
warranted.  
Future technical directions may include extracting a “flat-map” of the hippocampus, and 
look at changes in the CA1-CA3, CA4 or Dendate Gyrus, and Subiculum substructures, which 
have been demonstrated to be differentially sensitive to both encoding and memory retrieval of 
facial stimuli (Zeineh et al., 2003).  
Most importantly, prospective studies are needed, particularly surrounding manipulation 
of asthma control to elucidate the brain-behavior relationships observed in asthma. These 
relations are likely bidirectional and multifactorial. As these studies have been safely conducted 
(Weersnick et al., 1997; , incorporating a neuroimaging component to treatment intervention 
studies would provide substantial clarity to this field and further identify opportunities and 











In conclusion, the present study corroborates previous findings that individuals with 
asthma may have poorer behavioral memory retrieval for some, but not all memory tasks. In 
addition, when asked to make a memory decision, individuals with asthma tended to recruit 
additional areas of the right inferior frontal cortex (RIFC) compared to age and gender matched 
controls, suggesting that they may be working harder when completing the same type of memory 
task and achieving the same total accuracy as healthy controls. These findings provide novel 
insights into neural contributions to neurocognition in asthma and continue to underscore the 
importance of studying the neural processes in asthma and monitoring for neurocognitive 
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